Keep pulling the thread on Robert Blum.
China is restricting overseas travel for top AI professionals from private firms such as Alibaba and Deepseek.
The United States lacks a national industrial policy and commitment to science and medicine, making it harder to build biotech companies.
The United States is ceding its competitive advantage in biotechnology to China due to China's deliberate strategic commitment to industrializing the sector.
Cytokinetics launched its first commercial medicine earlier this year.
Cytokinetics incurred a net operating deficit of $3 to $4 billion over its 28-year history to reach the point of commercialization.
For years, Beijing has imposed travel restrictions on key personnel, including prominent college researchers, nuclear scientists, and executives at state-owned firms.
A Nobel-winning chemist is leaving the U.S. to direct an AI materials lab in China.
Cytokinetics has a market capitalization of nearly $11 billion.
The stock of Cytokinetics has increased by approximately 27% year-to-date.
It would be far more difficult to build a company like Cytokinetics today than when it was founded.
The lack of a U.S. national vision for science and medicine has become a more acute problem over the last 2 to 3 years.
The erosion of U.S. pharmaceutical leadership begins with the commoditization of pharmaceutical ingredients and extends through the supply chain to clinical trials and medicine availability.